Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have emerged as
promising therapeutic options for addressing Type‐2 diabetes, obesity, and related …

In the past few decades, childhood obesity has become a significant global health issue,
impacting around 107.7 million children and adolescents globally. There is currently minimal …

Glaucomatous neurodegeneration, a blinding disease affecting millions worldwide, has a
need for the exploration of new and effective therapies. Previously, the glucagon-like …

Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) is associated with the
excessive collection of lipids in hepatocytes. Over 75% of diabetes patients typically have …

Summary Background The benefit of Glucagon-like Peptide-1 (GLP-1) receptor agonists
(RAs) in weight reduction against potential harms remains unclear. This study aimed at …

Recent publicity around the use of new antiobesity medications (AOMs) has focused the
attention of patients and healthcare providers on the role of pharmacotherapy in the …

Simple Summary In this review paper, we outline the role of GLP-1-RAs in potentially
influencing PCa development and progression. While GLP-1-RAs show promise in inhibiting …

Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent metabolic disease, although
prevalence could change according to region, nowadays is considered a public health …

UK guidelines recommend liraglutide 3.0 mg in adults treated within specialist weight
management services with BMI≥ 35 kg/m2, prediabetes and high cardiovascular disease …

OBJECTIVE: Obesity presents an enduring and multifaceted dilemma that impacts
individuals, society, economies, and healthcare systems alike. Glucagon-like peptide-1 …